Callan Capital’s ResMed RMD Stock Holding History

Callan Capital’s Portfolio RMD Stock Details RMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q3	–	Sell	-16,183	Closed	-$1.02M	–	57
2016 Q2	$1.02M	Sell	16,183 -4,458	-22%	-$263K	0.42%	29
2016 Q1	$1.19M	Sell	20,641 -4,500	-18%	-$255K	0.5%	25
2015 Q4	$1.35M	Sell	25,141 -4,500	-15%	-$254K	0.53%	26
2015 Q3	$1.51M	Buy	+29,641	New	+$1.6M	0.82%	21

Other funds holding RMD

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.26% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

CBOA

Commonwealth Bank of Australia Sydney, NSW, Australia $355M AUM

Schroder Investment Management Group London, United Kingdom $141B AUM 34.18% 1-Year Est. Return

Callan Capital's RMD Position: Q3 2016 in Review

Callan Capital sold out of ResMed (RMD) in Q3 2016, closing a stake of 16,183 shares — an estimated $1.02M sold.

Callan Capital first reported a position in RMD in Q3 2015 and held it in 4 quarters. The position peaked at $1.51M in Q3 2015. 374 funds tracked by Wall St. Rank hold RMD as of Q3 2016.

Callan Capital reported no remaining ResMed position as of Q3 2016 after selling out during the quarter.
Callan Capital sold 16,183 ResMed shares in Q3 2016, an estimated $1.02M.
Callan Capital first reported a position in ResMed in Q3 2015 and held it in 4 quarters.
Callan Capital's ResMed position peaked at $1.51M in Q3 2015.
374 funds tracked by Wall St. Rank held ResMed as of Q3 2016.

Based on Callan Capital's 13F filing for Q3 2016, filed 15 Nov 2016.